Preview Mode Links will not work in preview mode

Oct 22, 2020

Featuring a roundtable discussion with Drs Andrew J Armstrong, Celestia S Higano, David F Penson and Neal D Shore on the following topics:

  • Optimizing the Choice of Therapy for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    • Selection of chemotherapy or secondary hormonal therapy (enzalutamide, abiraterone, apalutamide) to administer with androgen deprivation therapy (ADT) (0:00)
    • Management of HSPC in patients with de novo asymptomatic metastases (9:04)
    • Use of secondary hormonal therapy or chemotherapy in addition to ADT for patients with mHSPC in community-based practices (15:53)
    • Effect of patient age and comorbidities on choice of therapy for mHSPC (21:15)
    • Clinical outcomes with the addition of chemotherapy or secondary hormonal therapy to ADT for patients with mHSPC (29:42)
    • Tolerability and side-effect profiles of abiraterone/prednisone and enzalutamide (33:32)
    • Paradigm shift in the management of mHSPC — Neal D Shore, MD (37:36)
    • Case: A man in his late 60s with mHSPC achieves a good clinical response to ADT and apalutamide (53:51)
    • Case: A man in his early 50s with HSPC and extensive bone metastases (55:11)
    • Overall survival outcomes with the addition of secondary hormonal therapy or chemotherapy to ADT; management of the primary tumor in patients with mHSPC (57:35)
    • Practical factors influencing the selection of therapy for patients with mHSPC — David F Penson, MD, MPH, MMHC (1:02:39)
    • Case: A man in his late 50s with mHSPC and a BRCA2 mutation receives abiraterone and prednisone after treatment with docetaxel and ADT (1:21:49)
    • Balancing the risks and benefits of secondary hormonal therapy (1:25:47)
  • Selection and Sequencing of Therapies for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    • Choice of therapy based on symptoms and site of metastases for patients with mCRPC (1:27:28)
    • Management of mCRPC after disease progression on secondary hormonal therapy; testing for AR-V7 to predict resistance (1:32:29)
    • Clinical experience with the PARP inhibitors olaparib and rucaparib; activity of cabazitaxel in patients with mCRPC (1:36:54)
    • Recent FDA approval of rucaparib and olaparib for mCRPC; implications for genetic testing and routine practice (1:39:40)
    • Sequencing of therapies for men with mCRPC — Celestia S Higano, MD (1:46:36)
    • Promising agents and strategies for men with metastatic prostate cancer — Andrew J Armstrong, MD, ScM (2:04:40)

CME information and select publications